Cost–effectiveness and impact on quality of life of alefacept in the treatment of psoriasis

References

• Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. A randomized, double-blind, placebo-controlled Phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J. Am. Acad. Dermatol.47(6), 821–833 (2002).
   PubMed Web of Science ®Google Scholar
• Wong VK, Lebwohl M. The use of alefacept in the treatment of psoriasis. Skin Therapy Lett.8(6), 1–2, 7 (2003).
   PubMedGoogle Scholar
• Lowe NJ, Gonzalez J, Bagel J, Caro I, Ellis CN, Menter A. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int. J. Dermatol.42(3), 224–230 (2003).
   PubMed Web of Science ®Google Scholar
• Gordon KB, Vaishnaw AK, O’Gorman J, Haney J, Menter A. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch. Dermatol.139(12), 1563–1570 (2003).
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. An international, randomized, double-blind, placebo-controlled Phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch. Dermatol.139(6), 719–727 (2003).
   PubMed Web of Science ®Google Scholar
• Drug Administration, Center for Drug Evaluation and Research. COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. (5th Edition). Rockville, MD, US FDA. Publication FDA/CDER-95/24 (1995)
   Google Scholar
• Gordon KB, Langley RG. Remittive effects of intramuscular alefacept in psoriasis. J. Drugs Dermatol.2(6), 624–628 (2003).
   PubMedGoogle Scholar
• Gribetz CH, Blum R, Brady C, Cohen S, Lebwohl M. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J. Am. Acad. Dermatol.53(1), 73–75 (2005).
   PubMed Web of Science ®Google Scholar
• Goffe B, Papp K, Gratton D, Krueger GG. Long-term safety of alefacept in patients who have received up to nine courses of therapy. J. Am. Acad. Dermatol.52, P190 (2005) (Abstract P2773).
   Google Scholar
• Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Arch. Dermatol.137(6), 778–783 (2001).
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch. Dermatol.139(11), 1425–1429 (2003).
   PubMed Web of Science ®Google Scholar
• Krueger GG, Callis KP. Development and use of alefacept to treat psoriasis. J. Am. Acad. Dermatol.49(Suppl. 2), S87–S97 (2003).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Casale TB, Frankel E et al. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J. Am. Acad. Dermatol.49(5), 816–825 (2003).
   PubMed Web of Science ®Google Scholar
• Menter MA, Cather JC, Abromovits W. Tuberculosis testing and the use of biologic therapies for the treatment of psoriasis. J. Am. Acad. Dermatol.50, Poster 687 (2004) (Abstract P176).
   Google Scholar
• Thaci D, Patzold S, Kaufmann R, Boehncke WH. Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases. Br. J. Dermatol.152(5), 1048–1050 (2005).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Boehncke WH, Darif M. Safety and efficacy of alefacept in elderly patients and other special populations. J. Drugs Dermatol.4(6), 718–724 (2005).
   PubMedGoogle Scholar
• Chamian F, Lowes MA, Lin SL et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc. Natl Acad. Sci. USA102(6), 2075–2080 (2005).
   PubMed Web of Science ®Google Scholar
• da Silva AJ, Brickelmaier M, Majeau GR et al. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2+ cells. J. Immunol.168(9), 4462–4471 (2002).
   PubMed Web of Science ®Google Scholar
• Haider AS, Lowes MA, Gardner H et al. Novel insight into the agonistic mechanism of alefacept in vivo: differentially expressed genes may serve as biomarkers of response in psoriasis patients. J. Immunol.178(11), 7442–7449 (2007).
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. Alefacept: a safety profile. Expert Opin. Drug Saf.4(6), 975–985 (2005).
   PubMedGoogle Scholar
• Fivenson DP, Mathes B. Treatment of generalized lichen planus with alefacept. Arch. Dermatol.142(2), 151–152 (2006).
   PubMed Web of Science ®Google Scholar
• Heffernan MP, Hurley MY, Martin KS, Smith DI, Anadkat MJ. Alefacept for alopecia areata. Arch. Dermatol.141(12), 1513–1516 (2005).
   PubMed Web of Science ®Google Scholar
• Shapira MY, Resnick IB, Bitan M et al. Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report. Bone Marrow Transplant.36(12), 1097–1101 (2005).
   PubMed Web of Science ®Google Scholar
• Chi GC, Hsu FS, Yang CC, Wei JC. Scleroderma and failed response to alefacept. Rheumatology (Oxford)44(10), 1328–1330 (2005).
   PubMedGoogle Scholar
• Korver JE, van de Kerkhof PC, Pasch MC. Alefacept treatment of psoriatic nail disease: how severe should nail psoriasis be? J. Am. Acad. Dermatol.54(4), 742–743 (2006).
   PubMedGoogle Scholar
• Parrish CA, Sobera JO, Robbins CM, Cantrell WC, Desmond RA, Elewski BE. Alefacept in the treatment of psoriatic nail disease: a proof of concept study. J. Drugs Dermatol.5(4), 339–340 (2006).
   PubMedGoogle Scholar
• Myers W, Christiansen L, Gottlieb AB. Treatment of palmoplantar psoriasis with intramuscular alefacept. J. Am. Acad. Dermatol.53(2 Suppl. 1), S127–129 (2005).
   PubMed Web of Science ®Google Scholar
• Sweetser MT, Woodworth J, Swan S, Ticho B. Results of a randomized open-label crossover study of the bioequivalence of subcutaneous versus intramuscular administration of alefacept. Dermatol. Online J.12(3), 1 (2006).
   PubMedGoogle Scholar
• Strober BE. Successful treatment of plaque psoriasis with self-administered subcutaneous alefacept. Arch. Dermatol.141(12), 1602 (2005).
   PubMedGoogle Scholar
• Goffe B, Papp K, Gratton D et al. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin. Ther.27(12), 1912–1921 (2005).
   PubMed Web of Science ®Google Scholar
• Schmidt A, Robbins J, Zic J. Transformed mycosis fungoides developing after treatment with alefacept. J. Am. Acad. Dermatol.53(2), 355–356 (2005).
   PubMedGoogle Scholar
• Prasertsuntarasai T, Bello EF. Mycobacterium avium complex olecranon bursitis in a patient treated with alefacept. Mayo Clin. Proc.80(11), 1532–1533 (2005).
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Menter A. Efficacy and safety of alefacept in combination with methotrexate in the treatment of psoriatic arthritis. Presented at: the Summer Academy 2005 of the American Academy of Dermatology. Chicago, IL, USA, 20–24 July 2005 (Poster).
   Google Scholar
• Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum.54(5), 1638–1645 (2006).
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. Therapy-resistant psoriasis treated with alefacept and subsequent narrow band ultraviolet B phototherapy with total clearing of psoriasis. Dermatol. Online J.11(2), 7 (2005).
   PubMedGoogle Scholar
• Koo JY, Bagel J, Sweetser MT, Ticho BS. Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study. J. Drugs Dermatol.5(7), 623–628 (2006).
   PubMedGoogle Scholar
• Ortonne JP, Khemis A, Koo JY, Choi J. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis. J. Eur. Acad. Dermatol. Venereol.19(5), 556–563 (2005).
   PubMed Web of Science ®Google Scholar
• Krell JM. Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept. J. Am. Acad. Dermatol.54(6), 1099–1101 (2006).
   PubMedGoogle Scholar
• Hodulik SG, Zeichner JA. Combination therapy with acitretin for psoriasis. J. Dermatolog. Treat.17(2), 108–111 (2006).
   PubMed Web of Science ®Google Scholar
• Bovenschen HJ, Gerritsen WJ, de Jong EM, van de Kerkhof PC. Addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis. Acta Derm. Venereol.86(3), 281–282 (2006).
   PubMedGoogle Scholar
• van Duijnhoven MW, Korver JE, Vissers WH et al. Effect of calcipotriol on epidermal cell populations in alefacept-treated psoriatic lesions. J. Eur. Acad. Dermatol. Venereol.20(1), 27–33 (2006).
   PubMedGoogle Scholar
• Finlay AY, Salek MS, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology206(4), 307–315 (2003).
   PubMed Web of Science ®Google Scholar
• Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. New treatments for psoriasis: which biologic is best? J. Dermatolog. Treat.17(2), 96–107 (2006).
   PubMed Web of Science ®Google Scholar
• Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br. J. Dermatol.150(2), 317–326 (2004).
   PubMed Web of Science ®Google Scholar
• van de Kerkhof P, Griffiths CE, Christophers E, Lebwohl M, Krueger GG. Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate. Dermatology211(3), 256–263 (2005).
   PubMed Web of Science ®Google Scholar
• Krueger GG. Current concepts and review of alefacept in the treatment of psoriasis. Dermatol. Clin.22(4), 407–426, viii (2004).
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR. The promise and challenge of new biological treatments for psoriasis: how do they impact quality of life? Dermatol. Ther.17(5), 376–382 (2004).
   Google Scholar
• Menter A. The effect of psoriasis on patients’ quality of life and improvements associated with alefacept therapy. J. Cutan. Med. Surg.8(Suppl. 2), 20–25 (2004).
   PubMedGoogle Scholar
• Papp KA. The long-term efficacy and safety of new biological therapies for psoriasis. Arch. Dermatol. Res.298(1), 7–15 (2006).
   PubMed Web of Science ®Google Scholar
• Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol.137(3), 280–284 (2001).
   PubMed Web of Science ®Google Scholar
• Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled Phase II trial. Am. J. Clin. Dermatol.4(2), 131–139 (2003).
   PubMed Web of Science ®Google Scholar
• Bagel J. Efficacy and safety of multiple courses of alefacept in combination with UVB light and other psoriasis therapies. Presented at: the Summer Academy 2005 of the American Academy of Dermatology. Chicago, IL, USA, 20–24 July 2005 (Poster).
   Google Scholar
• Kraan MC, van Kuijk AW, Dinant HJ et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum.46(10), 2776–2784 (2002).
   PubMed Web of Science ®Google Scholar
• Nash P. Alefacept plus methotrexate for psoriatic arthritis. Nat. Clin. Pract. Rheumatol.2(9), 470–471 (2006).
   PubMedGoogle Scholar
• Gottlieb AB. Alefacept for psoriasis and psoriatic arthritis. Ann. Rheum. Dis.64(Suppl. 4), iv58–iv60 (2005).
   Google Scholar
• Malone DC, Ortmeier BG. Cost–effectiveness analysis of etanercept (Enbrel) versus infliximab (Remicade) in the treatment of rheumatoid arthritis patients. Presented at: The 66th Annual Scientific Meeting of the American College of Rheumatology. New Orleans, LA, USA, 25–29 October 2002 (Abstract 153).
   Google Scholar
• Iskedjian M, Barkovsky L, Desjardins O et al. Cost–effectiveness analysis of Amevive™ (alefacept) in the treatment of patients with moderate to severe psoriasis Presented at: the ISPOR 10th Annual International Meeting. Washington, DC, USA, 15–18 May 2005.
   Google Scholar
• Woolacott N, Hawkins N, Mason A et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol. Assess.10(46), 1–252 (2006).
   PubMedGoogle Scholar
• Parrish C, Elewski BE, Robbins C et al. The treatment of nail psoriasis with alefacept. Presented at: the Summer Academy 2005 of the American Academy of Dermatology. Chicago, IL, USA, 20–24 July 2005 (Poster).
   Google Scholar
• Pearce D, Feldman S, Carroll C et al. Open-label study of alefacept for the treatment of palmoplantar psoriasis. Presented at: the Summer Academy 2005 of the American Academy of Dermatology. Chicago, IL, USA, 20–24 July 2005 (Poster).
   Google Scholar
• Tan J, Yee LL, Zajner M et al. Efficacy and safety of an additional course of intramuscular alefacept in patients weighing 100–150 kg. Presented at: the Summer Academy 2005 of the American Academy of Dermatology. Chicago, IL, USA, 20–24 July 2005 (Poster).
   Google Scholar
• Feldman SR, McCarty MA, Pearce D et al. Alefacept plus broadband UVB therapy for chronic plaque psoriasis. Presented at: the Summer Academy 2005 of the American Academy of Dermatology. Chicago, IL, USA, 20–24 July 2005 (Poster).
   Google Scholar
• Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ. Quantifying the harmful effect of psoriasis on health-related quality of life. J. Am. Acad. Dermatol.47(4), 512–518 (2002).
   PubMed Web of Science ®Google Scholar
• Hazard E, Cherry SB, Lalla D, Woolley JM, Wilfehrt H, Chiou CF. Clinical and economic burden of psoriasis. Manag. Care Interface19(4), 20–26 (2006).
   PubMedGoogle Scholar
• Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br. J. Dermatol.132(2), 236–244 (1995).
   PubMed Web of Science ®Google Scholar
• Feldman SR, Garton R, Averett W, Balkrishnan R, Vallee J. Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin. Pharmacother.4(9), 1525–1533 (2003).
   PubMed Web of Science ®Google Scholar
• Pearce DJ, Nelson AA, Fleischer AB, Balkrishnan R, Feldman SR. The cost–effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J. Dermatolog. Treat.17(1), 29–37 (2006).
   PubMed Web of Science ®Google Scholar
• Hankin CS, Feldman SR, Szczotka A et al. A cost comparison of treatments of moderate to severe psoriasis. Drug Benefit Trends17, 200–214 (2005).
   Google Scholar
• Ortonne JP, Prinz JC. Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis. Eur. J. Dermatol.14(1), 41–45 (2004).
   Google Scholar
• Mease P. Psoriatic arthritis update. Bull. NYU Hosp. Jt. Dis.64(1–2), 25–31 (2006).
   PubMedGoogle Scholar
• van Duijnhoven MW, de Jong EM, Gerritsen WJ, Pasch MC, van de Kerkhof PC. Alefacept modifies long-term disease severity and improves the response to other treatments. Eur. J. Dermatol.15(5), 366–373 (2005).
   PubMedGoogle Scholar
• Lee MR, Cooper AJ. Use of infliximab in the treatment of psoriasis. Australas. J. Dermatol.45(3), 193–195 (2004).
   Google Scholar
• Bianchi L, Bergamin A, de Felice C, Capriotti E, Chimenti S. Remission and time of resolution of nail psoriasis during infliximab therapy. J. Am. Acad. Dermatol.52(4), 736–737 (2005).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J. Am. Acad. Dermatol.48(6), 829–835 (2003).
   PubMed Web of Science ®Google Scholar
• Goedkoop AY, de Rie MA, Picavet DI et al. Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch. Dermatol. Res.295(11), 465–473 (2004).
   PubMed Web of Science ®Google Scholar
• Woolacott N, Bravo Vergel Y, Hawkins N et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol. Assess.10(31), iii–iv, xiii–xvi, 1–239 (2006).
   PubMedGoogle Scholar
• Prossick TA, Belsito DV. Alefacept in the treatment of recalcitrant palmoplantar and erythrodermic psoriasis. Cutis78(3), 178–180 (2006).
   PubMed Web of Science ®Google Scholar
• Haider A, Garder H, Bandaru R et al. Rapid modulation of T cell associated genes after in vivo administration of alefacept may predict clinical response. J. Invest. Dermatol.124(Suppl. 4), Poster 282 (2005) (Abstract A47).
   Google Scholar
• Luba KM, Stulberg DL. Chronic plaque psoriasis. Am. Fam. Physician15(73), 636–644 (2006).
   Google Scholar